Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.

European journal of cancer (Oxford, England : 1990)（2023）

引用 1|浏览65

暂无评分

摘要

Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE.

查看译文

关键词

Bone metastases,Bone-targeting agent,Denosumab,Immune checkpoint inhibitors,Metastatic renal cell carcinoma,Nivolumab,Skeletal-related events,Survival analyses

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要